Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Immunity|March 6, 2016
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint BlockadePeter J R Ebert, Jeanne Cheung, Yagai Yang, et al.
Molecular & Cellular Proteomics : MCP|April 24, 2013
Systems-wide analysis of K-Ras, Cdc42, and PAK4 signaling by quantitative phosphoproteomicsFlorian Gnad, Amy Young, Wei Zhou, et al.
The Journal of Biological Chemistry|June 29, 2017
Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycleTaner Dogan, Florian Gnad, Jocelyn Chan, et al.
Cancer Research|November 16, 2011
Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibitionKlaus P Hoeflich, Mark Merchant, Christine Orr, et al.
Cancer Research|March 12, 2009
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppressionKlaus P Hoeflich, Sylvia Herter, Janet Tien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2010
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical modelsCarol O'Brien, Jeffrey J Wallin, Deepak Sampath, et al.
Genes & Cancer|July 24, 2014
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibitionKyle A Edgar, Lisa Crocker, Eric Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumabEvelyn Yao, Wei Zhou, Si Tuen Lee-Hoeflich, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 9, 2012
Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictionsEdna F Choo, Marcia Belvin, Jason Boggs, et al.
Journal of Medicinal Chemistry|April 18, 2012
Discovery of novel allosteric mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors possessing bidentate Ser212 interactionsRobert A Heald, Philip Jackson, Pascal Savy, et al.
Pageof 6